VentriPoint Diagnostics (TSE:VPT) has released an update.
VentriPoint Diagnostics has announced the submission of VMS+4.0, their latest AI-powered heart-scanning technology, to Health Canada for licensing as a new medical device. This cutting-edge technology promises MRI-quality cardiac imaging and aims to become an integral, non-invasive tool in cardiac care across Canada. Upon approval, the company plans to market this innovative system to enhance patient management for healthcare providers.
For further insights into TSE:VPT stock, check out TipRanks’ Stock Analysis page.
